Your Team for Swiss Law – désormais à Genève

Close

Que voudriez-vous rechercher?

Recherche du site
Filtres de recherche

Who's Who Legal (Switzerland 2019) - "Life Sciences"

"Stefan Kohler of Vischer is a well-known name in the Swiss market who possesses a strong reputation for his deep knowledge of IP regulation and contractual matters."

Legal 500 (EMEA 2019) - "Healthcare and Life Sciences" - Tier 1

"VISCHER is renowned for its expertise in corporate, commercial, transactional, regulatory and patent-related healthcare and biotech matters. Matthias Staehelin assisted Medartis with its initial public offering on the SIX Swiss Exchange, while Stefan Kohler acted for Novo Nordisk Pharma in its appeal against a pricing decision made by the Swiss Federal Office of Public Health concerning the client's type-two diabetes product. Christian Wyss advised Lundbeck on its €905m acquisition of Prexton Therapeutics."

Chambers Europe (2019) - "Life Sciences"

"A client describes Christian Wyss as "practical and knowledgeable" and another adds that "working with him is very easy and his responses are always on time." He acts for clients from the life sciences sector on financing and transactional matters, and assisted JSR Corporation with the Swiss aspects of its acquisition of Selexis. Wyss also advises on regulatory matters, such as research agreements and clinical trials."

Chambers Europe (2019) - "Life Sciences"

"Matthias Staehelin has significant experience in high-value transactional and financing work within the life sciences industry. His clients appreciate him for "his business acumen and ability to come up with practical solutions" and deem him to be a "pragmatic, assertive and solution-driven" practitioner."

Chambers Europe (2019) - "Life Sciences" - Band 1

"Stefan Kohler has a strong track record in regulatory matters and is recognised for his expertise in pricing-related issues and market access questions. He assisted Philip Morris International with the regulatory and liability aspects of the launch of its new product IQOS. A source describes him as "confident and solution-oriented" and lauds his capabilities in the pharmaceutical industry."

Who's Who Legal (Switzerland 2018) - "Life Sciences"

"Stefan Kohler at VISCHER is a key player in the market who sources describe as 'an excellent patent litigator', adding that he is also 'very strong at handling regulatory matters'."

Legal 500 (EMEA 2018) - "Healthcare and life sciences" - Tier 1

"Vischer provides transactional, financing, capital markets, product launch and regulatory advice to health and life sciences industry clients and further represents them in contentious matters. The practice assisted JSR Corporation with its acquisition of Selexis and advised Axovant Sciences on its debt financing agreement with Hercules Capital. Stefan Kohler jointly heads the practice with Matthias Staehelin; Christian Wyss is another name to note."

Chambers Europe (2018) - "Life Sciences"

"Christian Wyss enters the rankings for the first time on the back of strong client support. One client enthuses that he is 'responsive, knowledgeable, considerate and intelligent.' Another source notes that he is 'careful in listening to the needs of the customer' and is a 'clear communicator.' His work includes assisting T3 Pharmaceuticals with various financing and licence agreements. He has further capabilities advising on acquisitions and collaborative agreements within the life sciences sector."

Chambers Europe (2018) - "Life Sciences"

"Basel-based Matthias Staehelin has a strong focus on transactions, with experience handling high-stakes negotiations, licence agreements and incentive plans. He advised Polyphor on a CHF 40 million private placement and also acted for AC Immune on its IPO."

Chambers Europe (2018) - "Life Sciences"

"Stefan Kohler is 'very open and approachable,' according to one source, who also notes that he is a 'good adviser.' He successfully represented Novo Nordisk Pharma in an appeal regarding pricing orders and has further experience relating to negotiations and the implementation of new regulations, as well as compliance and liability risk issues."

You are currently offline. Some pages or content may fail to load.